1. Home
  2. FOLD vs NBTB Comparison

FOLD vs NBTB Comparison

Compare FOLD & NBTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • NBTB
  • Stock Information
  • Founded
  • FOLD 2002
  • NBTB 1856
  • Country
  • FOLD United States
  • NBTB United States
  • Employees
  • FOLD N/A
  • NBTB N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • NBTB Major Banks
  • Sector
  • FOLD Health Care
  • NBTB Finance
  • Exchange
  • FOLD Nasdaq
  • NBTB Nasdaq
  • Market Cap
  • FOLD 2.5B
  • NBTB 2.3B
  • IPO Year
  • FOLD 2007
  • NBTB N/A
  • Fundamental
  • Price
  • FOLD $8.15
  • NBTB $41.29
  • Analyst Decision
  • FOLD Strong Buy
  • NBTB Buy
  • Analyst Count
  • FOLD 9
  • NBTB 3
  • Target Price
  • FOLD $26.44
  • NBTB $52.33
  • AVG Volume (30 Days)
  • FOLD 5.8M
  • NBTB 188.4K
  • Earning Date
  • FOLD 11-05-2025
  • NBTB 10-27-2025
  • Dividend Yield
  • FOLD N/A
  • NBTB 3.59%
  • EPS Growth
  • FOLD N/A
  • NBTB 7.37
  • EPS
  • FOLD N/A
  • NBTB 2.77
  • Revenue
  • FOLD $571,160,000.00
  • NBTB $591,283,000.00
  • Revenue This Year
  • FOLD $20.98
  • NBTB $26.94
  • Revenue Next Year
  • FOLD $20.74
  • NBTB $11.40
  • P/E Ratio
  • FOLD N/A
  • NBTB $14.88
  • Revenue Growth
  • FOLD 25.35
  • NBTB 14.42
  • 52 Week Low
  • FOLD $5.51
  • NBTB $37.31
  • 52 Week High
  • FOLD $12.65
  • NBTB $52.44
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 56.40
  • NBTB 38.96
  • Support Level
  • FOLD $7.69
  • NBTB $40.90
  • Resistance Level
  • FOLD $8.59
  • NBTB $42.92
  • Average True Range (ATR)
  • FOLD 0.37
  • NBTB 0.87
  • MACD
  • FOLD -0.05
  • NBTB -0.19
  • Stochastic Oscillator
  • FOLD 54.44
  • NBTB 8.91

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.

Share on Social Networks: